Trial Profile
Switch to oral hypoglycemic agent therapy from insulin injection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2012
Price :
$35
*
At a glance
- Drugs Mitiglinide (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 Jan 2012 New trial record